We are live on
!
Find out more
TCM
Tang Capital Management Portfolio holdings
AUM
$1.97B
1-Year Est. Return
125.1%
This Fund
S&P 500
This Quarter
Est. Return
-1.54%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$216M
AUM Growth
+$9.73M
(+4.7%)
Cap. Flow
-$55.4M
Cap. Flow
% of AUM
-25.63%
Top 10 Holdings %
Top 10 Hldgs %
99.94%
Holding
14
New
–
Increased
2
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$7.95M |
| 2 |
Heron Therapeutics
HRTX
|
+$6.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MannKind Corp
MNKD
|
+$7.24M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$2.85M |
| 3 |
Phio Pharmaceuticals
PHIO
|
+$78K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Heron Therapeutics
HRTX
$86.3M
| $60.6M | 28.07% |
4,919,625
+510,638
| +12% | +$6.1M |
|
|
SLXP
2
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $37M | 17.14% |
300,000
| – | – |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $15.8M | 7.33% |
1,000,000
| – | – |
|
4
BioMarin Pharmaceuticals
BMRN
$11.5B
| $11.3M | 5.25% |
182,300
| – | – |
|
|
LJPC
5
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $8.1M | 3.75% |
881,907
+870,688
| +7,761% | +$7.95M |
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.77M | 2.67% |
288,432
-147,411
| -34% | -$2.85M |
|
|
ECYT
7
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $3.07M | 1.42% |
465,763
| – | – |
|
|
DNDN
8
DELISTED
DENDREON CORPORATION
DNDN
| $128K | 0.06% |
55,548
| – | – |
|
|
9
MannKind Corp
MNKD
$1.28B
| – | – |
-360,000
| Closed | -$7.24M |
|
|
10
Phio Pharmaceuticals
PHIO
$12.1M
| – | – |
0
| – | -$78K |
|
|
AMBI
11
DELISTED
Ambit Biosciences Corp
AMBI
| $0 | ﹤0.01% |
46
| – | – |
|
Similar funds
HA
SGAM
CCA
FWTB
NIM
RMCM
FC
SC
Tang Capital Management's Q2 2014 Portfolio in Review
As of Q2 2014, Tang Capital Management held 14 positions worth $216M, up 4.7% from $206M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Tang Capital Management withdrew a net $55.4M in Q2 2014, closing 1 position and reducing 1 holding. Its most notable exit was MannKind Corp, an estimated $7.24M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 56% a quarter earlier.
Against the trend, Tang Capital Management added an estimated $7.95M to La Jolla Pharmaceutical Company.
- Tang Capital Management added most to La Jolla Pharmaceutical Company in Q2 2014, an estimated $7.95M increase.
- Tang Capital Management's biggest Q2 2014 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $2.85M.
- Tang Capital Management fully exited MannKind Corp in Q2 2014, selling an estimated $7.24M.
- Tang Capital Management's ten largest holdings make up 100% of its $216M portfolio in Q2 2014.
- Tang Capital Management opened 0 new positions and closed 1 in Q2 2014.
- Tang Capital Management's portfolio value rose 4.7% quarter-over-quarter to $216M.
Based on Tang Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.